<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28453">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01958216</url>
  </required_header>
  <id_info>
    <org_study_id>RC11_0008</org_study_id>
    <nct_id>NCT01958216</nct_id>
  </id_info>
  <brief_title>in Vivo TICE (TransIntestinal Cholesterol Excretion)</brief_title>
  <acronym>in vivoTICE</acronym>
  <official_title>In Vivo TICE (TransIntestinal Cholesterol Excretion) Measurement in Bile Duct Diverted Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      So far, the liver has been the main target for cholesterol elimination. However, several
      recent studies performed in mice have described a new route of cholesterol excretion, the
      Trans-Intestinal Cholesterol Excretion or TICE. TICE allows direct elimination of plasma
      cholesterol in the feces directly via the intestine. Until now, only indirect evidence
      suggests that TICE is also active in humans, the goal of this proof of concept study is to
      provide the first proof of its existence in humans by using stable isotopes in patients with
      bile duct diversion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Measuring trans-intestinal cholesterol excretion in vivo in bile diverted patients</measure>
    <time_frame>Day 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measuring trans-intestinal cholesterol excretion in vivo in bile diverted patients</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Occlusion of Bile Duct With an External Bile Diversion.</condition>
  <arm_group>
    <arm_group_label>Trans-intestinal cholesterol excretion in vivo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Measuring trans-intestinal cholesterol excretion in vivo in bile diverted patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intravenous injection of deuterated cholesterol diluted in intralipid 20%</intervention_name>
    <description>At day 0, bile diverted patients will receive an intravenous injection of deuterated cholesterol diluted in intralipid 20%. The plasma, biliary and fecal content of deuterated cholesterol will be measured, by mass spectrometry, at 24, 48 and 72 hours after the initial input.</description>
    <arm_group_label>Trans-intestinal cholesterol excretion in vivo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - External bile duct diverted patients

        Exclusion Criteria:

          -  Inflammatory bowel disease

          -  Aphagia

          -  Renal or hepatocellular insufficiency

          -  Primary intestinal tumor

          -  Cholangitis or severe sepsis

          -  Acute or chronic diarrhea
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertrand Cariou, Pofessor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bertrand CARIOU, Professor</last_name>
    <phone>+33 (0)2 53 48 27 07</phone>
    <email>bertrand.cariou@univ-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cedric LE MAY, Doctor</last_name>
    <phone>+33 (0)2 28 08 01 66</phone>
    <email>Cedric.Lemay@univ-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand Cariou, Professor</last_name>
      <phone>+33 (0)2 53 48 27 07</phone>
      <email>bertrand.cariou@univ-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Bertrand Cariou, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>October 8, 2013</lastchanged_date>
  <firstreceived_date>September 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TICE-human-stable isotopes</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
